{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.6","upperLimit":"14.0","value":"8.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"The observed length of life from entry into the study to death or the date of last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"Pazopanib 800mg daily until disease progression or adverse effects prohibit further therapy (one cycle equals 28 days)","id":"OG000","title":"Pazopanib"}],"paramType":"MEDIAN","populationDescription":"Eligible and treated patients","reportingStatus":"POSTED","timeFrame":"Time from start of treatment to time of death or the date of last contact, assessed up to 5 years","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}